Association between funding sources and the scope and outcomes of cardiovascular clinical trials: A systematic review

International Journal of Cardiology

Volumn 230, Issue , 2017, Pages 301-303

  Vaduganathan, Muthiah ^a   Samman Tahhan, Ayman ^b   Patel, Ravi B ^c   Kelkar, Anita ^b   Papadimitriou, Lampros ^d   Georgiopoulou, Vasiliki V ^b   Greene, Stephen J ^e   Kalogeropoulos, Andreas P ^b   Peterson, Eric ^e   Fonarow, Gregg C ^f   Gheorghiade, Mihai ^c   Butler, Javed ^d  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b EMORY UNIVERSITY   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

^d STONY BROOK UNIVERSITY   (United States)

^e DUKE UNIVERSITY MEDICAL CENTER   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cardiovascular; Clinical trials; Funding source; Outcomes; Trial design

Indexed keywords

ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL PROTOCOL; CLINICAL RESEARCH; FINANCIAL MANAGEMENT; FUNDING; GOVERNMENT; HEALTH CARE INDUSTRY; HUMAN; MEDICAL LITERATURE; PEER REVIEW; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHASE 4 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; TREATMENT OUTCOME; CARDIOVASCULAR DISEASES; CLINICAL TRIAL (TOPIC); ECONOMICS; ORGANIZATION AND MANAGEMENT; OUTCOME ASSESSMENT;

CARDIOVASCULAR DISEASES; CLINICAL TRIALS AS TOPIC; FINANCING, ORGANIZED; HUMANS; OUTCOME ASSESSMENT (HEALTH CARE);

EID: 85009376655     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2016.12.119     Document Type: Article

References (10)

1. [1] Butler, J., Tahhan, A.S., Georgiopoulou, V.V., Kelkar, A., Lee, M., Khan, B., et al. Trends in characteristics of cardiovascular clinical trials 2001–2012. Am. Heart J. 170 (2015), 263–272.
2. [2] Califf, R.M., Zarin, D.A., Kramer, J.M., Sherman, R.E., Aberle, L.H., Tasneem, A., Characteristics of clinical trials registered in ClinicalTrials.gov, 2007–2010. JAMA 307 (2012), 1838–1847.
3. [3] Butler, J., Subacius, H., Vaduganathan, M., Fonarow, G.C., Ambrosy, A.P., Konstam, M.A., et al. Relationship between clinical trial site enrollment with participant characteristics, protocol completion, and outcomes: insights from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan) trial. J. Am. Coll. Cardiol. 61 (2013), 571–579.
4. [4] Ehrhardt, S., Appel, L.J., Meinert, C.L., Trends in national institutes of health funding for clinical trials registered in ClinicalTrials.gov. JAMA 314 (2015), 2566–2567.
5. [5] Ridker, P.M., Torres, J., Reported outcomes in major cardiovascular clinical trials funded by for-profit and not-for-profit organizations: 2000–2005. JAMA 295 (2006), 2270–2274.
6. [6] Hopewell, S., Loudon, K., Clarke, M.J., Oxman, A.D., Dickersin, K., Publication bias in clinical trials due to statistical significance or direction of trial results. Cochrane Database Syst. Rev., 2009, MR000006.
7. [7] Bhandari, M., Busse, J.W., Jackowski, D., Montori, V.M., Schunemann, H., Sprague, S., et al. Association between industry funding and statistically significant pro-industry findings in medical and surgical randomized trials. CMAJ 170 (2004), 477–480.
8. [8] Lexchin, J., Bero, L.A., Djulbegovic, B., Clark, O., Pharmaceutical industry sponsorship and research outcome and quality: systematic review. BMJ 326 (2003), 1167–1170.
9. [9] Chopra, S.S., Industry funding of clinical trials: benefit or bias?. JAMA 290 (2003), 113–114.
10. [10] Als-Nielsen, B., Chen, W., Gluud, C., Kjaergard, L.L., Association of funding and conclusions in randomized drug trials: a reflection of treatment effect or adverse events?. JAMA 290 (2003), 921–928.